← The Wire
JNJNYSE
JOHNSON & JOHNSON
Pharmaceutical Preparations · NJ · CIK 200406
Johnson & Johnson researches, manufactures, and sells a broad range of healthcare products
🔥 High media attention
$579.83B
Market cap
$258.51
Last close
+1.5%
1D
+11.8%
5D
8.6M
Volume
Price · last 39 sessions+15.3%
May 4L $221.32 · H $258.51Jun 29
260
Total filings
Jun 25, 2026
Last filing
01/03
Fiscal year end
DEFA14ADEFA14AMar 11, 2026DEFA14ADEFA14AMar 12, 2025DEFA14ADEFA14AMar 13, 2024DEFA14ADEFA14AMar 13, 2024DEFA14ADEFA14AJan 8, 2024DEFA14ADEFA14AApr 19, 2023DEFA14ADEFA14AApr 13, 2023DEFA14ADEFA14AMar 28, 2023DEFA14ADEFA14AMar 15, 2023DEFA14ADEFA14AMar 15, 2023DEFA14ADEFA14AMar 17, 2022DEFA14ADEFA14AMar 16, 2022DEFA14ADEFA14AApr 12, 2021DEFA14ADEFA14AMar 10, 2021DEFA14ADEFA14AMar 31, 2020DEFA14ADEFA14AMar 27, 2020DEFA14ADEFA14AMar 11, 2020DEFA14ADEFA14AApr 3, 2019DEFA14ADEFA14AMar 13, 2019DEFA14ADEFA14AMar 14, 2018
Insider Activity
In the 90 days to Feb 27, 2026: 7 sold $80.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 | Decker Robert JVP Corporate Controller | Sell | 4,075 | $247.87 | $1.0M |
| Feb 20, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $325K |
| Feb 18, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sell | 13,625 | $244.20 | $3.3M |
| Feb 18, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sell | 8,998 | $244.53 | $2.2M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 33,386 | $242.75 | $8.1M |
| Feb 17, 2026 | Reed John CEVP, Innovative Medicine, R&D | Sell | 29,927 | $243.00 | $7.3M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 24,961 | $242.68 | $6.1M |
| Feb 17, 2026 | Reed John CEVP, Innovative Medicine, R&D | Sell | 21,721 | $243.00 | $5.3M |
| Feb 17, 2026 | Swanson James D.EVP, CIO | Sell | 20,521 | $242.70 | $5.0M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 19,241 | $242.99 | $4.7M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 12,066 | $242.87 | $2.9M |
| Feb 17, 2026 | Broadhurst VanessaEVP, Global Corp Affairs | Sell | 6,197 | $243.39 | $1.5M |
| Feb 17, 2026 | Reed John CEVP, Innovative Medicine, R&D | Sell | 2,283 | $243.00 | $555K |
| Feb 13, 2026 | Swanson James D.EVP, CIO | Sell | 22,191 | $243.71 | $5.4M |
| Feb 13, 2026 | Swanson James D.EVP, CIO | Sell | 19,368 | $243.76 | $4.7M |
| Jan 26, 2026 | Duato JoaquinCEO and Chairman of the Board | Sell | 51,218 | $220.99 | $11.3M |
| Jan 26, 2026 | Duato JoaquinCEO and Chairman of the Board | Sell | 48,782 | $221.48 | $10.8M |
| Nov 26, 2025 | Morikis John GDirector | Buy | 1,250 | $206.15 | $258K |
| Oct 17, 2025 | Reed John CEVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
What Changed
Risk factors · Feb 13, 2025 → Feb 11, 202612 added · 3 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.
Newly disclosed
- Risks related to the planned separation of our Orthopaedics business The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results In October 2025, the Company announced its intention to separate the Company's Orthopaedics business.
- Completion of the planned separation will be subject to the satisfaction of certain conditions, including, among others, consultations with works councils and other employee representative bodies, as may be required, final approval of the Company's Board of Directors, and receipt of other regulatory approvals.
- Unanticipated developments could delay, prevent or otherwise adversely affect the planned separation, including but not limited to disruptions in general or financial market conditions or potential problems or delays in obtaining various regulatory approvals or clearances.
- In addition, the Company may be unable to achieve some of the strategic and financial benefits that it expects to achieve from the planned separation of the Company's Orthopaedics business The Company will incur significant expenses in connection with the planned separation.
- Following the planned separation, the price of shares of the Company's common stock may fluctuate significantly The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and market value of shares of its common stock may be less than, equal to or greater than the market value of shares of its common stock prior to the planned separation.
- Changes in tax laws or regulations in the U.S. and around the world, including global minimum taxes could negatively impact the Company’s effective tax rate and results of operations.
- In addition, the Company may not be able to achieve the full strategic and financial benefits that are expected to result from the planned separation.
- There can be no assurance regarding the ultimate timing of the planned separation or that such separation will be completed.
- The anticipated benefits of the planned separation are based on a number of assumptions, some of which may prove incorrect.
- In addition, the price of the Company's common stock may be more volatile around the time of the planned separation.
- The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.
- The costs to complete the planned separation will be significant.
No longer disclosed
- Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, such as the enactment by certain EU and non-EU countries, and the anticipated enactment by additional countries, of a global minimum tax, could negatively impact the Company’s effective tax rate and results of operations.
- In addition, the U.S. government recently announced tariffs on products manufactured in several jurisdictions, including China, Mexico and Canada, and has 14 made announcements regarding the potential imposition of tariffs on other jurisdictions.
- Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
In the News
🔥 High media attentionCoverage (30d): 2 reputable articles · skews ▲ positive.
WSJJohnson & Johnson to Buy Firefly Bio for $1 Billion21d agoReutersJ&J prostate cancer drug reduces risk of cancer spread and death in late-stage study29d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance